Novartis receives 2005 Excellence in Corporate Philanthropy Award
Novartis was honored with the 2005 Excellence in Corporate Philanthropy Award from the Committee to Encourage Corporate Philanthropy (CECP) - a distinguished recognition of the company's worldwide corporate citizenship activities that benefit millions of patients in need every year. Novartis is the first European company to win the Excellence Award from CECP, which has presented the honors annually since 2000 to companies demonstrating outstanding executive commitment, dedication to measurement and innovation in corporate philanthropy.
Novartis was recognized for its efforts to increase access to medicines for patients who cannot afford treatment. In 2004, over 4.25 million patients around the world benefited from Novartis programs valued at USD 570 million. These initiatives range from drug donation and research programs to combat neglected diseases like leprosy, tuberculosis and malaria in developing nations to patient assistance programs that help cancer patients receive the most innovative and effective treatments available.
"We are committed to applying our core strengths in discovering, developing, producing and distributing high quality medicines to ensure that patients around the world receive the treatments they need," said Dr. Daniel Vasella, Chairman and CEO of Novartis. "This award recognizes the work of Novartis associates around the globe who every day dedicate their work to provide patients with effective medicines and contribute to facilitate access to medicines for patients regardless of their ability to pay."
Other news from the department business & finance
